Plus Therapeutics Receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment from said benefits rates Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Austin, Texas, Sept. 01, 2020 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation (https://www.accessdata.fda.gov/script...) for its lead investigational drug, Rhenium NanoLiposomes (RNL™) for the treatment of patients with recurrent glioblastoma. nnRNL is being evaluated in the NIH/NCI-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial (NCT01906385)(h